The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
Top Cited Papers
Open Access
- 1 February 2017
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (2) , 338-346
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancerAnnals of Oncology, 2013
- Intermediate hepatocellular carcinoma: current treatments and future perspectivesAnnals of Oncology, 2013
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisAnnals of Oncology, 2012
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinomaCancer, 2010
- Hepatocellular Carcinoma – Epidemiological Trends and Risk FactorsDigestive Diseases, 2009
- Assessment of Prognosis of CirrhosisSeminars in Liver Disease, 2008
- A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantationLiver Transplantation, 2006
- Systematic review: the model for end‐stage liver disease – should it replace Child‐Pugh's classification for assessing prognosis in cirrhosis?Alimentary Pharmacology & Therapeutics, 2005
- Model for end-stage liver disease (MELD) and allocation of donor liversGastroenterology, 2003